Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R, Attard G, Van Allen EM, Tran PT, Spratt DE, Dittamore R, Davicioni E, Liu G, DiPaola R, Carducci MA, Sweeney CJ. Hamid AA, et al. Among authors: liu g. Ann Oncol. 2021 Sep;32(9):1157-1166. doi: 10.1016/j.annonc.2021.06.003. Epub 2021 Jun 12. Ann Oncol. 2021. PMID: 34129855 Free PMC article. Clinical Trial.
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Armstrong AJ, et al. Among authors: liu g. Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. Ann Oncol. 2018. PMID: 29088323 Free PMC article. No abstract available.
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Rathkopf DE, et al. Among authors: liu g. Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283. Ann Oncol. 2017. PMID: 28633425 Free PMC article. Clinical Trial.
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Zurita AJ, et al. Among authors: liu g. Ann Oncol. 2012 Mar;23(3):688-694. doi: 10.1093/annonc/mdr349. Epub 2011 Aug 5. Ann Oncol. 2012. PMID: 21821830 Free PMC article. Clinical Trial.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, Baumgartinger R, Adam PJ, Solca F, Kraut N, Nguyen HM, Corey E, Liu G, Sprenger CC, Plymate SR, Bogenrieder T. Weyer-Czernilofsky U, et al. Among authors: liu g. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. doi: 10.1158/1535-7163.MCT-19-0378. Epub 2020 Feb 13. Mol Cancer Ther. 2020. PMID: 32054790 Free PMC article.
34,902 results
You have reached the last available page of results. Please see the User Guide for more information.